Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52024XC05166

    Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2024 to 31 July 2024

    PUB/2024/799

    OJ C, C/2024/5166, 30.8.2024, ELI: http://data.europa.eu/eli/C/2024/5166/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    ELI: http://data.europa.eu/eli/C/2024/5166/oj

    European flag

    Official Journal
    of the European Union

    EN

    C series


    C/2024/5166

    30.8.2024

    Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 July 2024 to 31 July 2024

    (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council  (1) or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council  (2) )

    (C/2024/5166)

    Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

    Date of the decision

    Name of the medicinal product

    INN (International Non-Proprietary Name)

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Pharmaceutical form

    ATC code (Anatomical Therapeutic Chemical Code)

    Date of notification

    24.7.2024

    Apexelsin

    Paclitaxel

    WhiteOak Pharmaceutical B.V.

    Teleportboulevard 130, Amsterdam, 1043 EJ, Nederland

    EU/1/24/1835

    Powder for dispersion for infusion

    L01CD01

    26.7.2024

    24.7.2024

    Cejemly

    sugemalimab

    SFL Pharmaceuticals Deutschland GmbH

    Marie-Curie-Strasse 8, 79539 Loerrach, Deutschland

    EU/1/24/1833

    Concentrate for solution for infusion

    L01FF11

    25.7.2024

    24.7.2024

    DURVEQTIX

    fidanacogene elaparvovec

    Pfizer Europe MA EEIG

    Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België

    EU/1/24/1838

    Concentrate for solution for infusion

    Pending

    26.7.2024

    24.7.2024

    Kinpeygo

    budesonide

    STADA Arzneimittel AG

    Stadastraße 2-18, 61118 Bad Vilbel, Deutschland

    EU/1/22/1657

    Modified-release capsule, hard

    A07EA06

    29.7.2024

    24.7.2024

    Pomalidomide Krka

    pomalidomide

    KRKA d d., Novo mesto

    Šmarješka cesta 6, 8501 Novo mesto, Slovenija

    EU/1/24/1832

    Capsule, hard

    L04AX06

    25.7.2024

    24.7.2024

    Pomalidomide Zentiva

    pomalidomide

    Zentiva, k.s.

    U Kabelovny 130, 102 37 Praha 10, Česká republika

    EU/1/24/1830

    Capsule, hard

    L04AX06

    25.7.2024

    24.7.2024

    Zegalogue

    Dasiglucagon

    Zealand Pharma A/S

    Sydmarken 11, 2860 Soeborg, Danmark

    EU/1/24/1829

    Solution for injection

    H04AA02

    25.7.2024

    26.7.2024

    Avzivi

    Bevacizumab

    FGK Representative Service GmbH

    Heimeranstrasse 35, 80339 München, Deutschland

    EU/1/24/1834

    Concentrate for solution for infusion

    L01FG01

    30.7.2024

    26.7.2024

    Dasatinib Accord Healthcare

    dasatinib

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España

    EU/1/24/1839

    Film-coated tablet

    L01EA02

    29.7.2024

    26.7.2024

    Pomalidomide Accord

    pomalidomide

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España

    EU/1/24/1831

    Capsule, hard

    L04AX06

    29.7.2024

    Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    22.7.2024

    Nezglyal

    Minoryx Therapeutics S.L.

    Calle Ernest Lluch 32 Tcm 3, 08302 Mataro, España

    -

    23.7.2024

    Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    3.7.2024

    Comirnaty

    BioNTech Manufacturing GmbH

    An der Goldgrube 12, 55131 Mainz, Deutschland

    EU/1/20/1528

    4.7.2024

    5.7.2024

    Aldara

    Viatris Healthcare Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, Ireland

    EU/1/98/080

    8.7.2024

    5.7.2024

    Carbaglu

    Recordati Rare Diseases

    Immeuble Le Wilson, 70 avenue du Général de Gaulle, 92800 Puteaux, France

    EU/1/02/246

    10.7.2024

    5.7.2024

    Cosentyx

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/14/980

    8.7.2024

    5.7.2024

    Darunavir Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/16/1140

    8.7.2024

    5.7.2024

    Inrebic

    Bristol-Myers Squibb Pharma EEIG

    Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland

    EU/1/20/1514

    8.7.2024

    5.7.2024

    Iressa

    AstraZeneca AB

    151 85 Södertälje, Sverige

    EU/1/09/526

    8.7.2024

    5.7.2024

    Jylamvo

    Oresund Pharma ApS

    Orient Plads 1, 2150 Nordhavn, Hovedstaden, Danmark

    EU/1/17/1172

    8.7.2024

    5.7.2024

    Lonquex

    Teva B.V.

    Swensweg 5, 2031 GA Haarlem, Nederland

    EU/1/13/856

    8.7.2024

    5.7.2024

    Neulasta

    Amgen Europe B.V.

    Minervum 7061, 4817 ZK Breda, Nederland

    EU/1/02/227

    8.7.2024

    5.7.2024

    NovoMix

    Novo Nordisk A/S

    Novo Allé, 2880 Bagsvaerd, Danmark

    EU/1/00/142

    8.7.2024

    5.7.2024

    Pergoveris

    Merck Europe B.V.

    Gustav Mahlerplein 102, 1082 MA Amsterdam, Nederland

    EU/1/07/396

    8.7.2024

    5.7.2024

    Ristaben

    Merck Sharp & Dohme B.V.

    Waarderweg 39, 2031 BN Haarlem, Nederland

    EU/1/10/621

    9.7.2024

    5.7.2024

    Ronapreve

    Roche Registration GmbH

    Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland

    EU/1/21/1601

    8.7.2024

    5.7.2024

    Saxenda

    Novo Nordisk A/S

    Novo Allé, 2880 Bagsvaerd, Danmark

    EU/1/15/992

    8.7.2024

    5.7.2024

    Sibnayal

    ADVICENNE

    262, rue du Faubourg Saint Honoré 75008 Paris, France

    EU/1/20/1517

    8.7.2024

    5.7.2024

    Temozolomide Accord

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España

    EU/1/10/615

    8.7.2024

    5.7.2024

    Tigecycline Accord

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España

    EU/1/19/1394

    8.7.2024

    5.7.2024

    TUKYSA

    Pfizer Europe MA EEIG

    Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België

    EU/1/20/1526

    11.7.2024

    5.7.2024

    ZTALMY

    Marinus Pharmaceuticals Emerald Limited

    10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland

    EU/1/23/1743

    10.7.2024

    8.7.2024

    Sugammadex Amomed

    AOP Orphan Pharmaceuticals GmbH

    Leopold-Ungar-Platz 2, 1190 Wien, Österreich

    EU/1/22/1708

    11.7.2024

    8.7.2024

    Tevimbra

    BeiGene Ireland Limited

    10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland

    EU/1/23/1758

    9.7.2024

    8.7.2024

    Victoza

    Novo Nordisk A/S

    Novo Allé, 2880 Bagsvaerd, Danmark

    EU/1/09/529

    9.7.2024

    12.7.2024

    Ocaliva

    ADVANZ PHARMA Limited

    Suite 17, Northwood House, Northwood Avenue, Santry, Dublin 9, Ireland

    EU/1/16/1139

    15.7.2024

    12.7.2024

    Ristfor

    Merck Sharp & Dohme B.V.

    Waarderweg 39, 2031 BN Haarlem, Nederland

    EU/1/10/620

    16.7.2024

    12.7.2024

    Soliris

    Alexion Europe SAS

    103-105 rue Anatole France, 92300 Levallois-Perret, France

    EU/1/07/393

    15.7.2024

    17.7.2024

    Accofil

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona, s/n, Edifici Est 6a planta, 08039 Barcelona, España

    EU/1/14/946

    18.7.2024

    17.7.2024

    Fluenz

    AstraZeneca AB

    151 85 Södertälje, Sverige

    EU/1/24/1816

    18.7.2024

    17.7.2024

    Galvus

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/07/414

    18.7.2024

    17.7.2024

    GAVRETO

    Blueprint Medicines (Netherlands) B.V.

    Gustav Mahlerplein 2, 1082 MA Amsterdam, Nederland

    EU/1/21/1555

    18.7.2024

    17.7.2024

    Minjuvi

    Incyte Biosciences Distribution B.V.

    Paasheuvelweg 25, 1105 BP Amsterdam, Nederland

    EU/1/21/1570

    18.7.2024

    17.7.2024

    Rekovelle

    Ferring Pharmaceuticals A/S

    Amager Strandvej 405, 2770 Kastrup, Danmark

    EU/1/16/1150

    23.7.2024

    17.7.2024

    Ritonavir Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/17/1242

    18.7.2024

    17.7.2024

    Tepkinly

    AbbVie Deutschland GmbH & Co. KG

    Knollstrasse, 67061 Ludwigshafen, Deutschland

    EU/1/23/1759

    18.7.2024

    18.7.2024

    Levetiracetam SUN

    Sun Pharmaceutical Industries Europe BV

    Polarisavenue 87, 2132 JH Hoofddorp, Nederland

    EU/1/11/741

    25.7.2024

    18.7.2024

    Retacrit

    Pfizer Europe MA EEIG

    Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België

    EU/1/07/431

    18.7.2024

    19.7.2024

    Hyrimoz

    Sandoz GmbH

    Biochemiestrasse 10, 6250 Kundl, Österreich

    EU/1/18/1286

    22.7.2024

    19.7.2024

    Piqray

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/20/1455

    22.7.2024

    19.7.2024

    Pregabalin Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/15/997

    24.7.2024

    19.7.2024

    Scemblix

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/22/1670

    22.7.2024

    19.7.2024

    Votrient

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/10/628

    22.7.2024

    22.7.2024

    Avonex

    Biogen Netherlands B.V.

    Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland

    EU/1/97/033

    23.7.2024

    22.7.2024

    Byfavo

    PAION Pharma GmbH

    Heussstraße 25, 52078 Aachen, Deutschland

    EU/1/20/1505

    25.7.2024

    22.7.2024

    Deferasirox Mylan

    Mylan Pharmaceuticals Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/19/1386

    23.7.2024

    22.7.2024

    Norvir

    AbbVie Deutschland GmbH & Co. KG

    Knollstrasse, 67061 Ludwigshafen, Deutschland

    EU/1/96/016

    23.7.2024

    22.7.2024

    Slenyto

    RAD Neurim Pharmaceuticals EEC SARL

    4 rue de Marivaux, 75002 Paris, France

    EU/1/18/1318

    25.7.2024

    22.7.2024

    Teriflunomide Mylan

    Mylan Pharmaceuticals Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/22/1698

    23.7.2024

    22.7.2024

    VITRAKVI

    Bayer AG

    D-51368 Leverkusen, Deutschland

    EU/1/19/1385

    23.7.2024

    23.7.2024

    Prometax

    Almirall, S.A.

    Ronda General Mitre, 151, 08022 Barcelona, España

    EU/1/98/092

    25.7.2024

    24.7.2024

    AUBAGIO

    Sanofi Winthrop Industrie

    82 avenue Raspail, 94250 Gentilly, France

    EU/1/13/838

    25.7.2024

    24.7.2024

    Buvidal

    Camurus AB

    Ideon Science Park, 223 70 Lund, Sverige

    EU/1/18/1336

    25.7.2024

    24.7.2024

    Bydureon

    AstraZeneca AB

    151 85 Södertälje, Sverige

    EU/1/11/696

    25.7.2024

    24.7.2024

    Bylvay

    Ipsen Pharma

    65 quai Georges Gorse, 92100 Boulogne-Billancourt, France

    EU/1/21/1566

    29.7.2024

    24.7.2024

    Caprelsa

    Sanofi B.V.

    Paasheuvelweg 25, 1105 BP Amsterdam, Nederland

    EU/1/11/749

    25.7.2024

    24.7.2024

    Fluad Tetra

    Seqirus Netherlands B.V.

    Paasheuvelweg 28, 1105 BJ Amsterdam, Nederland

    EU/1/20/1433

    25.7.2024

    24.7.2024

    Flucelvax Tetra

    Seqirus Netherlands B.V.

    Paasheuvelweg 28, 1105 BJ Amsterdam, Nederland

    EU/1/18/1326

    25.7.2024

    24.7.2024

    Idefirix

    Hansa Biopharma AB

    P.O. Box 785, 220 07 Lund, Sverige

    EU/1/20/1471

    25.7.2024

    24.7.2024

    Ilumetri

    Almirall, S.A.

    Ronda General Mitre, 151, 08022 Barcelona, España

    EU/1/18/1323

    29.7.2024

    24.7.2024

    JCOVDEN

    Janssen-Cilag International NV

    Turnhoutseweg 30, 2340 Beerse, België

    EU/1/20/1525

    25.7.2024

    24.7.2024

    Kaletra

    AbbVie Deutschland GmbH & Co. KG

    Knollstrasse, 67061 Ludwigshafen, Deutschland

    EU/1/01/172

    25.7.2024

    24.7.2024

    Leflunomide medac

    medac Gesellschaft für klinische Spezialpräparate mbH

    Theaterstraße 6, 22880 Wedel, Deutschland

    EU/1/10/637

    25.7.2024

    24.7.2024

    Leflunomide Zentiva

    Zentiva k.s.

    U kabelovny 130, 102 37 Praha 10, Česká republika

    EU/1/09/604

    29.7.2024

    24.7.2024

    Mvabea

    Janssen-Cilag International NV

    Turnhoutseweg 30, 2340 Beerse, België

    EU/1/20/1445

    25.7.2024

    24.7.2024

    Nexavar

    Bayer AG

    D-51368 Leverkusen, Deutschland

    EU/1/06/342

    25.7.2024

    24.7.2024

    Pregabalin Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/15/997

    25.7.2024

    24.7.2024

    Pyzchiva

    Samsung Bioepis NL B.V.

    Olof Palmestraat 10, 2616 LR Delft, Nederland

    EU/1/24/1801

    30.7.2024

    24.7.2024

    Skyrizi

    AbbVie Deutschland GmbH & Co. KG

    Knollstrasse, 67061 Ludwigshafen, Deutschland

    EU/1/19/1361

    25.7.2024

    24.7.2024

    Suboxone

    Indivior Europe Limited

    27 Windsor Place, Dublin 2, D02 DK44, Ireland

    EU/1/06/359

    25.7.2024

    24.7.2024

    TUKYSA

    Pfizer Europe MA EEIG

    Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/ Pleinlaan 17, 1050 Brussel, België

    EU/1/20/1526

    30.7.2024

    26.7.2024

    Artesunate Amivas

    Amivas Ireland Ltd

    Suite 5, Second Floor, Station House, Railway Square, Waterford, Ireland

    EU/1/21/1582

    31.7.2024

    26.7.2024

    AYVAKYT

    Blueprint Medicines (Netherlands) B.V.

    Gustav Mahlerplein 2, 1082 MA Amsterdam, Nederland

    EU/1/20/1473

    29.7.2024

    26.7.2024

    Efficib

    Merck Sharp & Dohme B.V.

    Waarderweg 39, 2031 BN Haarlem, Nederland

    EU/1/08/457

    29.7.2024

    26.7.2024

    Eliquis

    Bristol-Myers Squibb/Pfizer EEIG

    Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland

    EU/1/11/691

    29.7.2024

    26.7.2024

    Epidyolex

    Jazz Pharmaceuticals Ireland Ltd

    5th Floor, Waterloo Exchange, Waterloo Road, Dublin D04 E5W7, Ireland

    EU/1/19/1389

    30.7.2024

    26.7.2024

    Fareston

    Orion Corporation

    Orionintie 1, 02200 Espoo, Suomi

    EU/1/96/004

    29.7.2024

    26.7.2024

    Imcivree

    Rhythm Pharmaceuticals Netherlands B.V.

    Radarweg 29, 1043 NX Amsterdam, Nederland

    EU/1/21/1564

    29.7.2024

    26.7.2024

    Imfinzi

    AstraZeneca AB

    151 85 Södertälje, Sverige

    EU/1/18/1322

    29.7.2024

    26.7.2024

    Janumet

    Merck Sharp & Dohme B.V.

    Waarderweg 39, 2031 BN Haarlem, Nederland

    EU/1/08/455

    29.7.2024

    26.7.2024

    Orladeyo

    Biocryst Ireland Limited

    Block 4, Harcourt Centre, Harcourt Road, Dublin 2, D02 HW77, Ireland

    EU/1/21/1544

    29.7.2024

    26.7.2024

    Quinsair

    Chiesi Farmaceutici S.p.A.

    Via Palermo 26/A, 43122 Parma, Italia

    EU/1/14/973

    31.7.2024

    26.7.2024

    Teriflunomide Accord

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España

    EU/1/22/1693

    29.7.2024

    26.7.2024

    Vabysmo

    Roche Registration GmbH

    Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland

    EU/1/22/1683

    29.7.2024

    26.7.2024

    Velmetia

    Merck Sharp & Dohme B.V.

    Waarderweg 39, 2031 BN Haarlem, Nederland

    EU/1/08/456

    29.7.2024

    26.7.2024

    Vumerity

    Biogen Netherlands B.V.

    Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland

    EU/1/21/1585

    31.7.2024

    26.7.2024

    Zubsolv

    Accord Healthcare S.L.U.

    World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, 08039 Barcelona, España

    EU/1/17/1233

    29.7.2024

    29.7.2024

    Atazanavir Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/16/1091

    30.7.2024

    29.7.2024

    Jalra

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/08/485

    1.8.2024

    29.7.2024

    Lopinavir/Ritonavir Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/15/1067

    30.7.2024

    29.7.2024

    Myalepta

    Chiesi Farmaceutici S.p.A.

    Via Palermo 26/A, 43122 Parma, Italia

    EU/1/18/1276

    30.7.2024

    29.7.2024

    Rasagiline Viatris

    Viatris Limited

    Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

    EU/1/16/1090

    30.7.2024

    29.7.2024

    Xiliarx

    Novartis Europharm Limited

    Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

    EU/1/08/486

    1.8.2024

    Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    5.7.2024

    Evicel

    Omrix Biopharmaceuticals N.V.

    Leonardo Da Vincilaan 15, 1831 Diegem, België

    EU/1/08/473

    8.7.2024

    5.7.2024

    Tizveni

    BeiGene Ireland Limited

    10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland

    EU/1/24/1797

    10.7.2024

    18.7.2024

    Esmya

    Gedeon Richter Plc.

    Gyömrői út 19-21, 1103 Budapest, Magyarország

    EU/1/12/750

    18.7.2024

    26.7.2024

    JCOVDEN

    Janssen-Cilag International NV

    Turnhoutseweg 30, 2340 Beerse, België

    EU/1/20/1525

    29.7.2024

    Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted

    Date of the decision

    Name of the medicinal product

    INN (International Non-Proprietary Name)

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Pharmaceutical form

    ATC code (Anatomical Therapeutic Chemical Code)

    Date of notification

    5.7.2024

    Nobilis Multriva RT+IBm+ND+Gm+REOm

    Avian metapneumovirus, avian infectious bronchitis virus, Newcastle disease virus, avian infectious bursal disease virus and avian reovirus vaccine (inactivated)

    Intervet International B.V.

    Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

    EU/2/24/317

    Emulsion for injection

    QI01AA26

    8.7.2024

    17.7.2024

    Nobilis Multriva RT+IBm+ND+EDS

    Avian metapneumovirus, infectious bronchitis virus, Newcastle disease virus and egg drop syndrome virus vaccine, inactivated.

    Intervet International B.V.

    Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

    EU/2/24/316

    Emulsion for injection

    Pending

    18.7.2024

    Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    5.7.2024

    Felpreva

    Vetoquinol S.A.

    Magny-Vernois, 70200 Lure, France

    EU/2/21/277

    8.7.2024

    5.7.2024

    Forceris

    Ceva Santé Animale

    10 avenue de La Ballastière, 33500 Libourne, France

    EU/2/19/235

    8.7.2024

    5.7.2024

    Isemid

    Ceva Santé Animale

    10 avenue de La Ballastière, 33500 Libourne, France

    EU/2/18/232

    9.7.2024

    5.7.2024

    Nobivac LoVo L4

    Intervet International B.V.

    Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

    EU/2/23/304

    8.7.2024

    5.7.2024

    Vectra 3D

    Ceva Santé Animale

    10 avenue de La Ballastière, 33500 Libourne, France

    EU/2/13/156

    8.7.2024

    5.7.2024

    Vectra Felis

    Ceva Santé Animale

    10 avenue de La Ballastière, 33500 Libourne, France

    EU/2/14/165

    8.7.2024

    5.7.2024

    Virbagen Omega

    VIRBAC

    1ère Avenue - 2065m – L.I.D., 06516 CARROS, France

    EU/2/01/030

    8.7.2024

    8.7.2024

    Circovac

    CEVA-Phylaxia Co. Ltd

    Szállás u. 5, 1107 Budapest, Magyarország

    EU/2/07/075

    10.7.2024

    8.7.2024

    HorStem

    EquiCord S.L

    103-D Loeches, Polígono. Industrial Ventorro del Cano, Alcorcón, 28925 Madrid, España.

    EU/2/18/226

    11.7.2024

    11.7.2024

    BLUEVAC BTV

    CZ Vaccines S.A.U.

    A Relva s/n – Torneiros 36410 O Porriño Pontevedra, España

    EU/2/11/122

    12.7.2024

    11.7.2024

    Porcilis AR-T DF

    Intervet International B.V.

    Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland

    EU/2/00/026

    12.7.2024

    Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

    European Medicines Agency

    Domenico Scarlattilaan 6

    1083 HS Amsterdam

    NETHERLANDS


    (1)   OJ L 136, 30.4.2004, p. 1, ELI: https://data.europa.eu/eli/reg/2004/726/oj .

    (2)   OJ L 4, 7.1.2019, p. 43, ELI: https://data.europa.eu/eli/reg/2019/6/oj .


    ELI: http://data.europa.eu/eli/C/2024/5166/oj

    ISSN 1977-091X (electronic edition)


    Top